Drug intelligence / Profile preview

ibuprofen + gamma-aminobutyric acid

Development stage
Approved
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination product containing **ibuprofen**, a nonsteroidal anti-inflammatory drug (NSAID), and **gamma-aminobutyric acid (GABA)**, an endogenous inhibitory neurotransmitter. Ibuprofen acts as a cyclooxygenase (COX) inhibitor to reduce prostaglandin synthesis, thus providing analgesic, anti-inflammatory, and antipyretic effects. Gamma-aminobutyric acid acts on GABA receptors in the central nervous system, leading to neuronal inhibition, though its efficacy as an oral supplement for pain or inflammation is not well established. The combination aims to manage pain and inflammation through both peripheral anti-inflammatory mechanisms (ibuprofen) and potential central neuromodulatory effects (GABA). Some formulations are marketed for dietary management of pain and inflammatory conditions[2][9].

Brand names
Theraprofen-800Theraprofen800Theraprofen 800Theraprofen-90Theraprofen90Theraprofen 90
Other names
ibuprofen + GABAibuprofen + gamma-aminobutyric acid kit
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)GABAA (Gamma-aminobutyric acid receptor)

Beyond the preview

Go deeper on ibuprofen + gamma-aminobutyric acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + gamma-aminobutyric acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call